Cargando…
Real-World Use of Alirocumab: Experience from a Large Healthcare Provider
With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C ta...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917622/ https://www.ncbi.nlm.nih.gov/pubmed/36769732 http://dx.doi.org/10.3390/jcm12031084 |
_version_ | 1784886411873222656 |
---|---|
author | Elis, Avishay Melzer Cohen, Cheli Chodick, Gabriel |
author_facet | Elis, Avishay Melzer Cohen, Cheli Chodick, Gabriel |
author_sort | Elis, Avishay |
collection | PubMed |
description | With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C target levels. Included were patients initiating treatment with alirocumab from 1 August 2016 to 1 May 2020, with blood lipids evaluations during baseline (180 days prior to therapy initiation) and after 120 (±60) days of follow-up. Patients with treatment intensification during the follow-up period were excluded. LDL-C change from baseline and reaching LDL-C target levels, according to 2019 ESC/EAS guidelines, were evaluated. Among 623 included patients, 50.2% were men, the mean age was 65 years (±9 y), 62% were classified as very-high risk, and 76% had statin intolerance. During the follow-up, 65% (n = 407) were treated only with alirocumab. In 90% the initiation dose was 75 mg, and 21% were up-titrated. Alirocumab was associated with a 31.7% reduction in LDL-C, with 20.5% of patients reaching target levels. In this RWE study, alirocumab was used primarily as a single agent for eligible patients. Suboptimal use and adherence to therapy may have led to a lower LDL-C reduction compared to previous RCTs and most reported real-world studies. |
format | Online Article Text |
id | pubmed-9917622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99176222023-02-11 Real-World Use of Alirocumab: Experience from a Large Healthcare Provider Elis, Avishay Melzer Cohen, Cheli Chodick, Gabriel J Clin Med Article With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C target levels. Included were patients initiating treatment with alirocumab from 1 August 2016 to 1 May 2020, with blood lipids evaluations during baseline (180 days prior to therapy initiation) and after 120 (±60) days of follow-up. Patients with treatment intensification during the follow-up period were excluded. LDL-C change from baseline and reaching LDL-C target levels, according to 2019 ESC/EAS guidelines, were evaluated. Among 623 included patients, 50.2% were men, the mean age was 65 years (±9 y), 62% were classified as very-high risk, and 76% had statin intolerance. During the follow-up, 65% (n = 407) were treated only with alirocumab. In 90% the initiation dose was 75 mg, and 21% were up-titrated. Alirocumab was associated with a 31.7% reduction in LDL-C, with 20.5% of patients reaching target levels. In this RWE study, alirocumab was used primarily as a single agent for eligible patients. Suboptimal use and adherence to therapy may have led to a lower LDL-C reduction compared to previous RCTs and most reported real-world studies. MDPI 2023-01-30 /pmc/articles/PMC9917622/ /pubmed/36769732 http://dx.doi.org/10.3390/jcm12031084 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elis, Avishay Melzer Cohen, Cheli Chodick, Gabriel Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title | Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title_full | Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title_fullStr | Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title_full_unstemmed | Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title_short | Real-World Use of Alirocumab: Experience from a Large Healthcare Provider |
title_sort | real-world use of alirocumab: experience from a large healthcare provider |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917622/ https://www.ncbi.nlm.nih.gov/pubmed/36769732 http://dx.doi.org/10.3390/jcm12031084 |
work_keys_str_mv | AT elisavishay realworlduseofalirocumabexperiencefromalargehealthcareprovider AT melzercohencheli realworlduseofalirocumabexperiencefromalargehealthcareprovider AT chodickgabriel realworlduseofalirocumabexperiencefromalargehealthcareprovider |